Results 201 to 210 of about 721,746 (293)
Increased calcification by erythrophagocytosis in aortic valvular interstitial cells
Abstract Background Calcific aortic valve disease (CAVD) progresses over time to severe aortic stenosis and eventually heart failure. Recent evidence indicates that intraleaflet haemorrhage (ILH) strongly promotes CAVD progression. However, it remains poorly understood how it mechanistically contributes to valvular calcification.
Zihan Qin +3 more
wiley +1 more source
Effects of sacubitril/valsartan on ventricular remodeling in patients with hypertension and maintenance hemodialysis: a retrospective cohort study. [PDF]
Jiang L +10 more
europepmc +1 more source
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao +27 more
wiley +1 more source
Left Ventricular Remodeling After Total Coronary Revascularization via Anterior Thoracotomy Versus Conventional Coronary Artery Bypass Grafting. [PDF]
Aslan V +3 more
europepmc +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
Early treatment with nootkatone prevents pressure overload-induced ventricular remodeling and heart failure. [PDF]
Liu Z +6 more
europepmc +1 more source
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source
The SGLT2 inhibitor dapagliflozin alleviates ventricular remodeling and apoptosis after myocardial infarction by inhibiting the TGF-β1 and MAPK pathways. [PDF]
Zhu Z +9 more
europepmc +1 more source

